EA200000352A1 - SIMPLE BISPHERE 1-OXA, AZA AND TIANAFTHALIN-2-ONE AS PHOSPHOLAMBAN INHIBITORS - Google Patents
SIMPLE BISPHERE 1-OXA, AZA AND TIANAFTHALIN-2-ONE AS PHOSPHOLAMBAN INHIBITORSInfo
- Publication number
- EA200000352A1 EA200000352A1 EA200000352A EA200000352A EA200000352A1 EA 200000352 A1 EA200000352 A1 EA 200000352A1 EA 200000352 A EA200000352 A EA 200000352A EA 200000352 A EA200000352 A EA 200000352A EA 200000352 A1 EA200000352 A1 EA 200000352A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alkyl
- aryl
- arylalkyl
- hydrogen
- alkenyl
- Prior art date
Links
- 102000005681 phospholamban Human genes 0.000 title abstract 2
- 108010059929 phospholamban Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 7
- 150000002431 hydrogen Chemical class 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- -1 CONRR Chemical class 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Терапевтически активные соединения формулы (I) или (II), где Rобозначает водород, алкил, алкенил, арил, арилалкил, гидроксиалкил, галогеналкил, алкокси, COR, CONRR, OR, S(O)R, NRCORили NRR, где Rобозначает водород, алкил, алкенил, арил, арилалкил, гидроксиалкил, галогеналкил, алкокси или гидрокси и Rобозначает водород, алкил, арил, арилалкил, алкокси, арилокси, гидрокси или ацил, или в случае, когда X обозначает NR, Rможет быть также карбоксилалкилом; Rобозначает водород, алкил, алкенил, арил, арилалкил; Rи Rобозначают водород, алкил, арил, арилалкил, алкенил, COR, CONRR, галоген, трифторметил, нитро или циано, где Rи Rобозначают то же, что и выше, Rобозначает водород, алкил, арил или арилалкил; A обозначает алкил или замещенный алкил; m обозначает 0-2 и n обозначает 1-3; Y обозначает O, NRили S, где Rобозначают то же, что и выше; X обозначает O, NRили S, где Rобозначает то же, что и выше, R, R, Rи Rобозначают независимо одну из следующих групп (a), (b), (c), (d), (e), (f), (g) или в случае, когда X обозначает NR, R, R, Rи Rмогут также независимо обозначать HOOC-, ROOC-, HNCO- или HOHNCO-, где Rобозначает алкил, арилалкил или арил, и где каждый остаток арил, определенный выше, сам по себе или как часть другой группы, может быть замещенным, и их фармацевтически приемлемые соли и сложные эфиры. Соединения имеют ингибирующую фосфоламбан активность и являются полезными для лечения сердечной недостаточности.Международная заявка была опубликована вместе с отчетом о международном поиске.Therapeutically active compounds of formula (I) or (II), where R denotes hydrogen, alkyl, alkenyl, aryl, arylalkyl, hydroxyalkyl, halogenoalkyl, alkoxy, COR, CONRR, OR, S (O) R, NRCOR or NRR, where R denotes hydrogen, alkyl , alkenyl, aryl, arylalkyl, hydroxyalkyl, haloalkyl, alkoxy or hydroxy, and R5 is hydrogen, alkyl, aryl, arylalkyl, alkoxy, aryloxy, hydroxy, or acyl, or in the case where X is NR, R may also be carboxylalkyl; R 4 is hydrogen, alkyl, alkenyl, aryl, arylalkyl; R5 and R4 are hydrogen, alkyl, aryl, arylalkyl, alkenyl, COR, CONRR, halogen, trifluoromethyl, nitro or cyano, where R1 and R4 are the same as above, R4 is hydrogen, alkyl, aryl or arylalkyl; A is alkyl or substituted alkyl; m is 0-2 and n is 1-3; Y is O, NR or S, where R </ i> is the same as above; X is O, NR or S, where R denotes the same as above, R, R, R and R denote independently one of the following groups (a), (b), (c), (d), (e), (f) , (g) or in the case when X is NR, R, R, R and R may also independently designate HOOC-, ROOC-, HNCO- or HOHNCO-, where R denotes alkyl, arylalkyl or aryl, and where each residue is aryl, as defined above , alone or as part of another group, may be substituted, and their pharmaceutically acceptable salts and esters. The compounds have phospholamban inhibitory activity and are useful for treating heart failure. The international application was published along with an international search report.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93711997A | 1997-09-24 | 1997-09-24 | |
| US99015097A | 1997-12-12 | 1997-12-12 | |
| US10411498A | 1998-06-25 | 1998-06-25 | |
| PCT/FI1998/000755 WO1999015523A1 (en) | 1997-09-24 | 1998-09-24 | Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200000352A1 true EA200000352A1 (en) | 2000-10-30 |
| EA003084B1 EA003084B1 (en) | 2002-12-26 |
Family
ID=27379660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200000352A EA003084B1 (en) | 1997-09-24 | 1998-09-24 | Bisethers of 1-oxa and 1-aza and naphthalen-2-ones as phospholamban inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1017691A1 (en) |
| JP (1) | JP2003525838A (en) |
| KR (1) | KR20010015607A (en) |
| CN (1) | CN1143857C (en) |
| AU (1) | AU735729B2 (en) |
| BR (1) | BR9813216A (en) |
| CA (1) | CA2304849A1 (en) |
| EA (1) | EA003084B1 (en) |
| EE (1) | EE04494B1 (en) |
| HU (1) | HUP0003647A3 (en) |
| ID (1) | ID24373A (en) |
| IL (1) | IL134662A0 (en) |
| NO (1) | NO20001569L (en) |
| NZ (1) | NZ503044A (en) |
| PL (1) | PL339493A1 (en) |
| SK (1) | SK3902000A3 (en) |
| TR (1) | TR200000764T2 (en) |
| WO (1) | WO1999015523A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002008217A2 (en) * | 2000-07-21 | 2002-01-31 | Chugai Seiyaku Kabushiki Kaisha | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| SI1373259T1 (en) * | 2001-03-30 | 2005-04-30 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| FR2970964B1 (en) * | 2011-01-28 | 2013-12-13 | Univ Claude Bernard Lyon | NOVEL AZACOUMARIN DERIVATIVES WITH INHIBITOR ACTIVITY OF MDR PUMPS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2543945A1 (en) * | 1975-10-02 | 1977-04-21 | Troponwerke Gmbh & Co Kg | Coronary dilator 2-benzopyranones, active by enteral admin. - contg. trimethoxybenzoyl or trimethoxycinnamoyl substits. |
| GB8529362D0 (en) * | 1985-11-28 | 1986-01-02 | Pfizer Ltd | Quinolone cardiac stimulants |
| GB8630702D0 (en) * | 1986-12-23 | 1987-02-04 | Wellcome Found | Quinoline compound |
| DK391189A (en) * | 1988-08-10 | 1990-02-11 | Otsuka Pharma Co Ltd | carbostyril derivatives |
| IE902750A1 (en) * | 1989-07-31 | 1991-02-27 | Sankyo Co | Coumarin derivatives, their preparation and their use in the¹treatment of cerebrovascular disorders |
| DE4337906A1 (en) * | 1993-11-08 | 1995-05-11 | Cassella Ag | Use of coumarin derivatives |
-
1998
- 1998-09-24 AU AU93508/98A patent/AU735729B2/en not_active Ceased
- 1998-09-24 NZ NZ503044A patent/NZ503044A/en unknown
- 1998-09-24 JP JP2000512828A patent/JP2003525838A/en active Pending
- 1998-09-24 BR BR9813216-4A patent/BR9813216A/en not_active IP Right Cessation
- 1998-09-24 KR KR1020007003094A patent/KR20010015607A/en not_active Ceased
- 1998-09-24 EE EEP200000179A patent/EE04494B1/en not_active IP Right Cessation
- 1998-09-24 HU HU0003647A patent/HUP0003647A3/en unknown
- 1998-09-24 EP EP98946482A patent/EP1017691A1/en not_active Withdrawn
- 1998-09-24 CN CNB98809438XA patent/CN1143857C/en not_active Expired - Fee Related
- 1998-09-24 EA EA200000352A patent/EA003084B1/en not_active IP Right Cessation
- 1998-09-24 ID IDW20000564A patent/ID24373A/en unknown
- 1998-09-24 IL IL13466298A patent/IL134662A0/en unknown
- 1998-09-24 TR TR2000/00764T patent/TR200000764T2/en unknown
- 1998-09-24 PL PL98339493A patent/PL339493A1/en unknown
- 1998-09-24 CA CA002304849A patent/CA2304849A1/en not_active Abandoned
- 1998-09-24 WO PCT/FI1998/000755 patent/WO1999015523A1/en not_active Ceased
- 1998-09-24 SK SK390-2000A patent/SK3902000A3/en unknown
-
2000
- 2000-03-24 NO NO20001569A patent/NO20001569L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9813216A (en) | 2000-08-29 |
| TR200000764T2 (en) | 2001-03-21 |
| JP2003525838A (en) | 2003-09-02 |
| AU9350898A (en) | 1999-04-12 |
| KR20010015607A (en) | 2001-02-26 |
| EA003084B1 (en) | 2002-12-26 |
| NO20001569D0 (en) | 2000-03-24 |
| NZ503044A (en) | 2001-08-31 |
| AU735729B2 (en) | 2001-07-12 |
| WO1999015523A1 (en) | 1999-04-01 |
| EP1017691A1 (en) | 2000-07-12 |
| ID24373A (en) | 2000-07-13 |
| CN1143857C (en) | 2004-03-31 |
| IL134662A0 (en) | 2001-04-30 |
| EE04494B1 (en) | 2005-06-15 |
| SK3902000A3 (en) | 2000-12-11 |
| NO20001569L (en) | 2000-03-24 |
| PL339493A1 (en) | 2000-12-18 |
| CA2304849A1 (en) | 1999-04-01 |
| HUP0003647A3 (en) | 2002-12-28 |
| HUP0003647A2 (en) | 2001-08-28 |
| CN1271357A (en) | 2000-10-25 |
| EE200000179A (en) | 2001-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA199800184A1 (en) | Benzimidazole compounds | |
| FR2639636B1 (en) | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | |
| EA199800943A1 (en) | UREA DERIVATIVES AND THEIR USE AS INHIBITORS INOSINE-5`-MONO-PHOSPHATE-DEHYDROGENASE INHIBITORS | |
| ATE139233T1 (en) | ANNELATED THIOPHENE DERIVATIVES, THEIR PREPARATION AND USE | |
| DK0622361T3 (en) | Heterocyclic compounds as bradykinin antagonists | |
| HUP0001446A2 (en) | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinone derivatives as hiv reverse transcriptase inhibitors, their use and pharmaceutical compositions containing them | |
| EP0948327A4 (en) | ANTIDIABETIC AGENTS | |
| NO982913L (en) | Quinoline and quinazoline compounds useful in therapy | |
| CY1112143T1 (en) | USE OF KYKLOPENTA [G] KINAZOLIN PRODUCTS FOR CANCER TREATMENT | |
| EA199800170A1 (en) | DERIVATIVES OF 2- (4-SUBSTITUTED) BENZYLAMINO-2-METHYL-PROPANAMIDE | |
| FR2679555B1 (en) | NEW DERIVATIVES OF UREAE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS. | |
| FR2725719B1 (en) | DIAZEPINO-INDOLES IV PHOSPHODIESTERASE INHIBITORS | |
| EA200000352A1 (en) | SIMPLE BISPHERE 1-OXA, AZA AND TIANAFTHALIN-2-ONE AS PHOSPHOLAMBAN INHIBITORS | |
| IE822310L (en) | Triazoloquinazolone derivatives | |
| NO960441L (en) | Benzopyrans and pharmaceutical compounds containing them | |
| CA2364719A1 (en) | 2-aminopyridines containing fused ring substituents | |
| ATE102199T1 (en) | 4-AMINO-3-CARBOXYNAPHTHYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | |
| NZ337749A (en) | Benzimidazole derivative and their use in allergy-related disease | |
| EA199800701A1 (en) | BENZO [S] QUINOLYSINUM DERIVATIVES, THEIR RECEIVING AND USE AS INHIBITORS 5a-REDUCTAZ | |
| DE60027908D1 (en) | UREA COMPOUNDS, A METHOD OF PREPARING THEM AND THEIR USE | |
| TR200001941T1 (en) | N-oxides of heterocyclic compounds with TNF and PDE-IV inhibitory activity. | |
| EP1144393A3 (en) | Heterocyclic derivatives and their use as integrin inhibitor | |
| ATE166872T1 (en) | BENZOTHIAZOLE DERIVATIVES | |
| EA199800085A1 (en) | METHOD FOR TREATING VISCERAL ORIGIN PAIN, METHOD FOR TREATING INFLAMMATORY COLITIS | |
| MX9202994A (en) | 2-AMINO ACETAMIDE DERIVATIVES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |